OncLive - Clinical Oncology News, Cancer Expert Insights
OncLive - Clinical Oncology News, Cancer Expert Insights
Spotlight
OncClub: Join the Chat on Trending Trials in CancerIn-person and virtual events just for HCPsLive Broadcast to Explore a Second Line Treatment Option for HER2+ Metastatic Breast Cancer Register to join us LIVE in Chicago for Giants of Cancer Care®Subscribe to our eNewsletter for breaking news and curated content
Specialty
View MoreBreast CancerCAR T-cell TherapyChronic Lymphocytic LeukemiaGastrointestinal CancerGenitourinary CancersGynecologic OncologyImmuno-OncologyLung CancerMelanoma & Skin CancerMultiple MyelomaUrothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
Rare Cancer Series
Media
Insights
Medical World News
News Network
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Thoracic Night Live
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Publications
Oncology Live
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Partners
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information

© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Spotlight
  • OncClub: Join the Chat on Trending Trials in Cancer
  • In-person and virtual events just for HCPs
  • Live Broadcast to Explore a Second Line Treatment Option for HER2+ Metastatic Breast Cancer
  • Register to join us LIVE in Chicago for Giants of Cancer Care®
  • Subscribe to our eNewsletter for breaking news and curated content
SpecialtySee All >
  • Breast Cancer
  • CAR T-cell Therapy
  • Chronic Lymphocytic Leukemia
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Urothelial Cancer
OncLive SOSS
  • Advertise
  • About OncLive
  • Editorial Board
  • CancerNetwork.com
  • CGTlive.com
  • CureToday.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

Julia Rotow, MD

  1. home

Articles

Dr. Rotow on Remaining Questions With Brigatinib in ALK+ NSCLC

January 31st 2020

Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non­–small cell lung cancer.

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

January 31st 2020

Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.

Dr. Rotow on First-Line Brigatinib Versus Crizotinib in ALK+ NSCLC

January 31st 2020

Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non

Dr. Rotow on Updated ALEX Trial Results in ALK+ NSCLC

January 17th 2020

Julia Rotow, MD, discusses updated data from the phase III ALEX trial in ALK-positive non–small cell lung cancer.

Dr. Rotow on Brigatinib Safety Profile in ALK+ NSCLC

January 2nd 2020

Julia Rotow, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.